Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer

2015481 citationsJournal Articlegreen Open Access

Authors

Andrew J. Gunderson · Oregon Health & Science University

Megan M. Kaneda · University of California San Diego

Takahiro Tsujikawa · Oregon Health & Science University

Abraham V. Nguyen · University of California San Diego

Nesrine I. Affara · University of California, San Francisco

Brian Ruffell · Oregon Health & Science University

Sara Gorjestani

Abstract

We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell-dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer.

Topics & Keywords

Phagocytosis and Immune Regulation Pancreatic function and diabetes Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Discovery

Volume 6, Issue 3, pp. 270-285

DOI: 10.1158/2159-8290.cd-15-0827

Field-Weighted Citation Impact: 17.71